About
Paolo Di Giorgio is the CEO and Managing Director of Angelini Ventures, with over 20 years of experience in venture capital, R&D, external innovation, and business development in the life sciences. Before founding Angelini Ventures, he served as Head of External Innovation R&D at Angelini Pharma and previously led drug discovery programs in neuropsychiatry and neurodegeneration at Novartis Pharma in Switzerland. He earned a PhD in Cellular and Molecular Biology from Harvard University and an MBA from IE Business School in Madrid, after graduating from the University of Bologna.
Contact· self-published, not guessed
Invests in
BiotechDigital Health
Experience
- Angelini VenturesFounder & CEOcurrent2021 — presentRome, Italy
- Extend | the National Technology Transfer Biotech HubBoard Membercurrent2022 — present
- Arclight TherapeuticsBoard Observercurrent2022 — presentBoston, Massachusetts, United States
- GenEpBoard Observercurrent2021 — present
- Pretzel TherapeuticsBoard Observercurrent2021 — present
- Angelini Lumira Bioscience Fund (ALBF)Member of the Investment committeecurrent2021 — present
- ARGOBIOBoard Membercurrent2021 — present
- Angelini PharmaHead of R&D and External Innovation2016 — 2021Roma, Italia
- NovartisBusiness Development2015 — 2016Basel Metropolitan Area
- NovartisProject team leader2011 — 2016Basel Metropolitan Area
- NovartisLaboratory head of neuroscience and stem cell biology2009 — 2016Basel, Basel, Switzerland
- Salk Institute for Biological StudiesPostdoctoral Fellow2008 — 2009San Diego County, California, United States
- Harvard UniversityPhD student & Postdoctoral Fellow2005 — 2008Greater Boston
- MerckPhD student2002 — 2005Rome, Latium, Italy
- EMBLIntern2000Heidelberg, Baden-Württemberg, Germany
Skills & more
Lifesciences12Biotechnology36Drug Discovery19Cell Biology33Drug Development10Clinical Development10Neuroscience13Pharmaceutical Industry8Assay Development4Life Sciences32Molecular Biology6Oncology4
+12 more
CellBusiness DevelopmentCross-functional Team LeadershipBusiness StrategyProgram ManagementProject ManagementDepartment ManagementResearch and Development (R&D)StrategyManagementStrategic PlanningLeadershipLanguages English · Italian
From Paolo's professional profile.
Investments
Board seats
ArgobioNeumirnaPretzel Therapeutics
Per the firm's website.
Colleagues at Angelini Ventures
Frequently asked questions
- Who is Paolo Di Giorgio?
- Paolo Di Giorgio is the CEO and Managing Director of Angelini Ventures, with over 20 years of experience in venture capital, R&D, external innovation, and business development in the life sciences. Before founding Angelini Ventures, he served as Head of External Innovation R&D at Angelini Pharma and previously led drug discovery programs in neuropsychiatry and neurodegeneration at Novartis Pharma in Switzerland. He earned a PhD in Cellular and Molecular Biology from Harvard University and an MBA from IE Business School in Madrid, after graduating from the University of Bologna.
- Where does Paolo Di Giorgio work?
- Paolo Di Giorgio is CEO and Managing Director at Angelini Ventures.
- What does Paolo Di Giorgio invest in?
- Paolo Di Giorgio invests in Biotech, Digital Health.
- What boards does Paolo Di Giorgio sit on?
- Paolo Di Giorgio holds tracked board seats at Argobio, Neumirna, Pretzel Therapeutics.
- Where did Paolo Di Giorgio go to school?
- Paolo Di Giorgio studied at Harvard University (Visiting scholar (Ph.D) and postdoctoral fellow, Neuroscience and stem cell biology); IE Business School (Master of Business Administration (M.B.A.)); Alma Mater Studiorum – Università di Bologna (Bachelor's degree, Biotechnology).
Same school
Also attended Harvard University1,971
Alfred LinPartner at Sequoia CapitalChris DixonFounder & Managing Partner of a16z crypto at Andreessen HorowitzSarah TavelVenture Partner at BenchmarkDanny RimerPartner at Index VenturesLaela SturdyManaging Partner at CapitalGBill GatesCo-founder of Microsoft; Chair of the Gates Foundation
+ 1,965 more
Also attended IE Business School281
Ben PerryInvestor at MedicxiYuhan XieInvestment Manager at Burda Principal InvestmentsBorja FernándezGeneral Partner at Inveready Technology Investment GroupGabriel FarmeInvestor at Graphene VenturesHayata TokizawaVice President at Fin CapitalAlessandro GiacomettiVice President, Head of Investor Relations at Vida Ventures
+ 275 more
Also attended Alma Mater Studiorum – Università di Bologna85
Edoardo MingozziPortfolio Support Analyst at P101 VenturesClare McCartney BeerCOO & Managing Director at Burda Principal InvestmentsIrene MingozziVenture Partner at E12 Venture Capital, LlcLuca BarbiGeneral Partner & COO at STVMariana RomeroSenior Associate at NazcaHannah ArrighiVice President at Center15 Capital
+ 79 more
Shared employers
Also worked at Novartis169
Rebecca JamesInvestor at Index VenturesScott BillerInvestor at GV (Google Ventures)Freya Svedberg-KeatingInvestor at MedicxiAndrea AmadorCompliance Manager at Inveready Technology Investment GroupAbbie CelnikerInvestor at Third Rock VenturesJesper GromadaInvestor at Third Rock Ventures
+ 163 more
Also worked at Salk Institute for Biological Studies19
Brittany de KouchkovskyDirector, University Relations at Osage University PartnersRichard HeymanVenture Partner at ARCH Venture PartnersMira ChaurushiyaManaging Director at Westlake Village BioPartnersChris WeyrerPrincipal at Vida VenturesAlex LoftisPrincipal at Vida VenturesManuel MontoyaSenior Associate, Software Engineering at Endeavor Catalyst
+ 13 more
Also worked at Harvard University361
Nathan BlecharczykCo-founder & CSO of AirbnbRyan SheaCo-founder of Blockstack (Stacks)Dave MunichielloInvestor at GV (Google Ventures)Nicole GaudelliEntrepreneur in Residence at GV (Google Ventures)Logan HilleLife Sciences Analyst at CincyTechWalter KowtoniukInvestor at Third Rock Ventures
+ 355 more
Also worked at Merck139
Sam BlackmanEntrepreneur in Residence at GV (Google Ventures)Catherine Pearce, DHSc, MBAAdvisor at CincyTechDavid MollerInvestor at Third Rock VenturesAlan EzekowitzInvestor at Third Rock VenturesAndrea van ElsasInvestor at Third Rock VenturesDavid KaufmanInvestor at Third Rock Ventures
+ 133 more